$JAN Did anyone actually take the time to read the actual details of this License Agreement? The Majority of the Financial and Milestone Objectives are "Redacted". Without the Transparency, an Investor can not properly evaluate this Deal. Essentially, this is putting $JAN as a MIddleman to resell this same License to other companies and the Treatment in question isn't even out of FDA Trials. It is a High Risk Move considering the company already has a hard time meeting their existing Obligations an their Geotraq Acquisition hasn't made them a Dime in over two years.